{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T14:34:08Z","timestamp":1771511648224,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1016\/j.atherosclerosis.2007.10.004","type":"journal-article","created":{"date-parts":[[2007,12,6]],"date-time":"2007-12-06T22:56:50Z","timestamp":1196981810000},"page":"313-319","source":"Crossref","is-referenced-by-count":24,"title":["Polymorphisms in the peroxisome proliferator activated receptor \u03b1 gene are associated with levels of apolipoprotein CIII and triglyceride in African-Americans but not Caucasians"],"prefix":"10.1016","volume":"198","author":[{"given":"Min-Jeong","family":"Shin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alka M.","family":"Kanaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald M.","family":"Krauss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2007.10.004_bib1","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00041433-199906000-00007","article-title":"Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis","volume":"10","author":"Fruchart","year":"1999","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2007.10.004_bib2","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0021-9150(94)90090-6","article-title":"The effects of fibrates in lipoprotein and hemostatic coronary risk factors","volume":"111","author":"Schonfeld","year":"1994","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2007.10.004_bib3","doi-asserted-by":"crossref","first-page":"5336","DOI":"10.1002\/j.1460-2075.1996.tb00918.x","article-title":"PPAR alpha and PPAR gamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene","volume":"15","author":"Schoonjans","year":"1996","journal-title":"EMBO J"},{"key":"10.1016\/j.atherosclerosis.2007.10.004_bib4","doi-asserted-by":"crossref","first-page":"13470","DOI":"10.1074\/jbc.270.22.13470","article-title":"Mode of action of peroxisome proliferators as hypolipidemic drugs, suppression of apolipoprotein C-III","volume":"270","author":"Hertz","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2007.10.004_bib5","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/S0022-2275(20)41090-9","article-title":"Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action","volume":"36","author":"Haubenwallner","year":"1995","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2007.10.004_bib6","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1172\/JCI117717","article-title":"Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates","volume":"95","author":"Staels","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.atherosclerosis.2007.10.004_bib7","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2007.10.004_bib8","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/0026-0495(92)90208-R","article-title":"A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition","volume":"41","author":"Bard","year":"1995","journal-title":"Metabolism"},{"key":"10.1016\/j.atherosclerosis.2007.10.004_bib9","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0021-9150(89)90221-9","article-title":"Lipoprotein composition changes induced by fenofibrate in dysbetalipoproteinemia type III","volume":"78","author":"Lussier-Cacan","year":"1989","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2007.10.004_bib10","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/00005344-200001000-00022","article-title":"Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state","volume":"35","author":"Genest","year":"2000","journal-title":"J Cadiovasc Pharmacol"},{"key":"10.1016\/j.atherosclerosis.2007.10.004_bib11","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/0021-9150(96)05854-6","article-title":"Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR","volume":"124","author":"Auwerx","year":"1996","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2007.10.004_bib12","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1161\/01.ATV.15.7.963","article-title":"Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E","volume":"15","author":"Clavey","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2007.10.004_bib13","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0022-2275(20)32037-X","article-title":"Molecular scanning of the human PPAR\u03b1 gene: association of the L162v mutation with hyperapobetalipoproteinemia","volume":"41","author":"Vohl","year":"2000","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2007.10.004_bib14","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.atherosclerosis.2005.08.034","article-title":"The L162V polymorphism at the peroxisome proliferator activated receptor alpha locus modulates the risk of cardiovascular events associated with insulin resistance and diabetes mellitus: the Veterans Affairs HDL Intervention Trial (VA-HIT)","volume":"187","author":"Tai","year":"2006","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2007.10.004_bib15","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s001250051357","article-title":"Variation in the PPAR\u03b1 gene is associated with altered function in vitro and plasma lipid concentrations in type II diabetic subjects","volume":"43","author":"Flavell","year":"2000","journal-title":"Diabetologia"},{"key":"10.1016\/j.atherosclerosis.2007.10.004_bib16","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1161\/01.CIR.0000012145.80593.25","article-title":"Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease","volume":"105","author":"Flavell","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2007.10.004_bib17","doi-asserted-by":"crossref","first-page":"582","DOI":"10.2337\/diabetes.54.2.582","article-title":"Peroxisome proliferator-activated receptor alpha gene variation influences age of onset and progression of type 2 diabetes","volume":"54","author":"Flavell","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.atherosclerosis.2007.10.004_bib18","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.amjcard.2005.09.134","article-title":"Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study","volume":"97","author":"Simon","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2007.10.004_bib19","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/clinchem\/31.2.217","article-title":"Comparison of improved precipitation methods or quantification of high-density lipoprotein cholesterol","volume":"31","author":"Warnick","year":"1985","journal-title":"Clin Chem"},{"key":"10.1016\/j.atherosclerosis.2007.10.004_bib20","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"10.1016\/j.atherosclerosis.2007.10.004_bib21","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: Insulin resistance and \u03b2-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Mathews","year":"1985","journal-title":"Diabetologia"},{"key":"10.1016\/j.atherosclerosis.2007.10.004_bib22","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/00008571-200006000-00006","article-title":"The human peroxisome proliferator-activated receptor [alpha] gene: identification and functional characterization of two natural allelic variants","volume":"10","author":"Sapone","year":"2000","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.atherosclerosis.2007.10.004_bib23","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1161\/01.ATV.0000012302.11991.42","article-title":"Association between the PPARA L162V polymorphism and plasma lipid levels: the Framingham Offspring Study","volume":"22","author":"Tai","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2007.10.004_bib24","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/00008571-200307000-00007","article-title":"Evidence for an association between the Leu162Val polymorphism of the PPAR[alpha] gene and decreased fasting serum triglyceride levels in glucose tolerant subjects","volume":"13","author":"Nielsen","year":"2003","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.atherosclerosis.2007.10.004_bib25","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/jn\/135.3.397","article-title":"Polyunsaturated fatty acids interact with the PPAR-L162V polymorphism to affect plasma triglyceride and apolipoprotein CIII concentrations in the Framingham Heart Study","volume":"135","author":"Tai","year":"2005","journal-title":"J Nutr"},{"key":"10.1016\/j.atherosclerosis.2007.10.004_bib26","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1210\/me.16.5.1013","article-title":"Characterization of the human PPARalpha promoter: identification of a functional nuclear receptor response element","volume":"16","author":"Pineda Torra","year":"2002","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.atherosclerosis.2007.10.004_bib27","first-page":"974","article-title":"Selective RXR modulators for the treatment of type II diabetes","volume":"5","author":"Faul","year":"2002","journal-title":"Curr Opin Drug Discov Devel"},{"key":"10.1016\/j.atherosclerosis.2007.10.004_bib28","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/79876","article-title":"Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus","volume":"26","author":"HorikawaY","year":"2000","journal-title":"Nat Genet"},{"key":"10.1016\/j.atherosclerosis.2007.10.004_bib29","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1056\/NEJM199804093381502","article-title":"Relation of alleles of the collagen type Ia1 gene to bone density and the risk of osteoporotic fractures in postmenopausal women","volume":"338","author":"Uitterlinden","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2007.10.004_bib30","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.atherosclerosis.2005.10.013","article-title":"Increased apolipoprotein C-III levels associated with insulin resistance contribute to dyslipidemia in normoglycemic and diabetic subjects from a triethnic population","volume":"188","author":"Florez","year":"2006","journal-title":"Atherosclerosis"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915007006569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915007006569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T02:46:19Z","timestamp":1630291579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915007006569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["S0021915007006569"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2007.10.004","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}